ASCO活指南2026.1.0版:I-III期HR阳性HER2阴性乳腺癌的药物治疗
ASCO活指南针对I-III期激素受体阳性、HER2阴性乳腺癌的药物治疗提供推荐。内分泌治疗仍是基础,特定患者可联合化疗和靶向治疗以降低复发和死亡风险。
要点
- 内分泌治疗是I-III期HR阳性HER2阴性乳腺癌的治疗基础。
- 特定患者可从化疗和靶向治疗中进一步获益。
- 治疗推荐应整合临床病理特征、基因组检测、患者偏好和复发风险。
核心结论
- 内分泌治疗仍是I-III期激素受体阳性、HER2阴性乳腺癌的治疗基石,特定患者联合化疗和靶向治疗可进一步降低复发和乳腺癌死亡风险。
关键数值与推荐
- 推荐按I-III期激素受体阳性、HER2阴性乳腺癌患者的纵向诊疗流程组织,涵盖从诊断到完成全身治疗的决策序列。
- 治疗推荐应整合临床病理特征、基因组检测、患者偏好、治疗耐受性和估计复发风险。
临床怎么用
- 临床医生应以内分泌治疗为基础,根据临床病理特征、基因组检测、患者偏好、耐受性和复发风险为特定患者选择化疗和靶向治疗并安排序贯治疗。
局限性
- 活指南不替代治疗医生的独立专业判断,也未考虑患者个体差异,且不适用于所有患者、干预措施、疾病或疾病分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE: To provide recommendations on use of medical therapies for patients with stage I to III hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and formulated recommendations for practice. Eligible studies included patients with stage I to III hormone receptor-positive, HER2-negative breast cancer and evaluated neoadjuvant or adjuvant chemotherapy, endocrine therapy (ET), immunotherapy, or targeted therapy. Outcomes of interest included pathologic complete response, disease-free survival, distant recurrence-free survival, overall survival, health-related quality of life, and treatment-related adverse effects. RESULTS: Forty-five randomized clinical trials (68 references) published from 2018 to 2026 were identified by the broad literature search. Supplemental searches identified six individual patient data meta-analyses and 21 retrospective studies that, combined with the primary clinical trials, informed guidance on which patients should receive treatment, which treatments should be selected, optimal treatment timing, duration of treatment, and approaches to support adherence. A final section addresses estimation of prognosis and treatment benefit to inform decisions across all phases of treatment. RECOMMENDATIONS: The recommendations are organized to follow the longitudinal care of patients with stage I to III hormone receptor-positive, HER2-negative breast cancer, reflecting the sequence of decisions faced by clinicians from diagnosis through completion of systemic therapy. ET remains the foundation of treatment for stage I to III hormone receptor-positive, HER2-negative breast cancer. For selected patients, chemotherapy and targeted therapies can further reduce the risk of recurrence and breast cancer death. Treatment recommendations should integrate clinicopathologic features, genomic assays, patient preferences, treatment tolerability, and estimated recurrence risk. The guideline provides evidence-based recommendations to support individualized treatment selection and sequencing across the continuum of care.Additional information is available on the ASCO Publications website.
引用
- Caswell-Jin JL, Somerfield MR, Khan MA, et al. Medical Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage I to III Breast Cancer: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. 2026. PMID: 42647767. doi:10.1200/JCO-26-02034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。